- Home
- TERN vs BTX Comparison
TERN vs BTX Comparison
Compare TERN & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- BTX
- Stock Information
- Founded
- TERN 2017
- BTX N/A
- Country
- TERN United States
- BTX United States
- Employees
- TERN N/A
- BTX N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- BTX
- Sector
- TERN Health Care
- BTX
- Exchange
- TERN Nasdaq
- BTX Nasdaq
- Market Cap
- TERN 713.2M
- BTX 765.6M
- IPO Year
- TERN 2021
- BTX N/A
- Fundamental
- Price
- TERN $8.39
- BTX $6.58
- Analyst Decision
- TERN Buy
- BTX
- Analyst Count
- TERN 7
- BTX 0
- Target Price
- TERN $14.99
- BTX N/A
- AVG Volume (30 Days)
- TERN 1.1M
- BTX 1.0M
- Earning Date
- TERN 11-11-2025
- BTX 11-01-2025
- Dividend Yield
- TERN N/A
- BTX 14.78%
- EPS Growth
- TERN N/A
- BTX N/A
- EPS
- TERN N/A
- BTX N/A
- Revenue
- TERN N/A
- BTX N/A
- Revenue This Year
- TERN N/A
- BTX N/A
- Revenue Next Year
- TERN N/A
- BTX N/A
- P/E Ratio
- TERN N/A
- BTX N/A
- Revenue Growth
- TERN N/A
- BTX N/A
- 52 Week Low
- TERN $1.87
- BTX $5.10
- 52 Week High
- TERN $9.03
- BTX $8.31
- Technical
- Relative Strength Index (RSI)
- TERN 58.46
- BTX 35.58
- Support Level
- TERN $7.91
- BTX $6.61
- Resistance Level
- TERN $9.03
- BTX $6.95
- Average True Range (ATR)
- TERN 0.42
- BTX 0.13
- MACD
- TERN -0.01
- BTX -0.02
- Stochastic Oscillator
- TERN 59.43
- BTX 16.37
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About BTX BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.